{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T19:18:59Z","timestamp":1758050339917,"version":"3.44.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T00:00:00Z","timestamp":1634342400000},"content-version":"am","delay-in-days":380,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.bulcan.2020.06.011","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T13:12:39Z","timestamp":1600348359000},"page":"1056-1068","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prise en charge des toxicit\u00e9s h\u00e9patiques sous immunoth\u00e9rapie anticanc\u00e9reuse"],"prefix":"10.1016","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3411-1580","authenticated-orcid":false,"given":"Fanny","family":"Leboss\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Bancel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Levrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Merle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2020.06.011_bib0255","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1146\/annurev.iy.12.040194.002005","article-title":"Tumor antigens recognized by T lymphocytes","volume":"12","author":"Boon","year":"1994","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"10.1016\/j.bulcan.2020.06.011_bib0260","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.immuni.2013.07.005","article-title":"Deciphering and reversing tumor immune suppression","volume":"39","author":"Motz","year":"2013","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.bulcan.2020.06.011_bib0265","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bulcan.2020.06.011_bib0270","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.coi.2014.01.002","article-title":"Orchestrating immune check-point blockade for cancer immunotherapy in combinations","volume":"27","author":"Perez-Gracia","year":"2014","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"10.1016\/j.bulcan.2020.06.011_bib0275","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00262-017-1954-6","article-title":"PD-1\u00a0and PD-L1\u00a0antibodies in cancer: current status and future directions","volume":"66","author":"Balar","year":"2017","journal-title":"Cancer Immunol Immunother CII"},{"issue":"8","key":"10.1016\/j.bulcan.2020.06.011_bib0280","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.bulcan.2020.06.011_bib0285","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3\u00a0trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2020.06.011_bib0290","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"10105","key":"10.1016\/j.bulcan.2020.06.011_bib0295","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3\u00a0study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet Lond Engl"},{"issue":"3","key":"10.1016\/j.bulcan.2020.06.011_bib0300","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1470-2045(15)00544-6","article-title":"Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.bulcan.2020.06.011_bib0305","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"10183","key":"10.1016\/j.bulcan.2020.06.011_bib0310","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3\u00a0trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet Lond Engl"},{"issue":"10066","key":"10.1016\/j.bulcan.2020.06.011_bib0315","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet Lond Engl"},{"issue":"10031","key":"10.1016\/j.bulcan.2020.06.011_bib0320","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2\u00a0trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet Lond Engl"},{"issue":"6","key":"10.1016\/j.bulcan.2020.06.011_bib0325","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/annonc\/mdz127","article-title":"Randomized phase III KEYNOTE-045\u00a0trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of>2\u00a0years of follow-up","volume":"30","author":"Fradet","year":"2019","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.bulcan.2020.06.011_bib0330","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"10122","key":"10.1016\/j.bulcan.2020.06.011_bib0335","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3\u00a0randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet Lond Engl"},{"issue":"10088","key":"10.1016\/j.bulcan.2020.06.011_bib0340","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2\u00a0dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet Lond Engl"},{"issue":"5_suppl","key":"10.1016\/j.bulcan.2020.06.011_bib0345","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/annonc\/mdz394.029","article-title":"CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)","volume":"30","author":"Yau","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2020.06.011_bib0350","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.4012","article-title":"Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): results from CheckMate 040","volume":"37","author":"Yau","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2020.06.011_bib0355","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Results of KEYNOTE-240: phase 3\u00a0study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC)","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2020.06.011_bib0360","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4\u00a0and anti-PD-1\u00a0antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bulcan.2020.06.011_bib0365","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bulcan.2020.06.011_bib0370","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). Protocol Development | CTEP [Internet]. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf (Accessed on March 09, 2018)."},{"issue":"20","key":"10.1016\/j.bulcan.2020.06.011_bib0375","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1002\/cncr.32339","article-title":"Phase 2\u00a0study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma","volume":"125","author":"Feun","year":"2019","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.bulcan.2020.06.011_bib0380","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2\u00a0cohort of the open-label KEYNOTE-021\u00a0study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"9807","key":"10.1016\/j.bulcan.2020.06.011_bib0385","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3\u00a0trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet Lond Engl"},{"issue":"12","key":"10.1016\/j.bulcan.2020.06.011_bib0390","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"10064","key":"10.1016\/j.bulcan.2020.06.011_bib0395","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3\u00a0trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet Lond Engl"},{"issue":"4_suppl","key":"10.1016\/j.bulcan.2020.06.011_bib0400","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1200\/JCO.2020.38.4_suppl.564","article-title":"Phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC)","volume":"38","author":"El-Khoueiry","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10126","key":"10.1016\/j.bulcan.2020.06.011_bib0405","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3\u00a0non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet Lond Engl"},{"issue":"13\u00a0Supplement","key":"10.1016\/j.bulcan.2020.06.011_bib0410","doi-asserted-by":"crossref","first-page":"CT061","DOI":"10.1158\/1538-7445.AM2019-CT061","article-title":"Abstract CT061: a phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): updated results","volume":"79","author":"Ikeda","year":"2019","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.bulcan.2020.06.011_bib0415","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"issue":"4_suppl","key":"10.1016\/j.bulcan.2020.06.011_bib0420","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1200\/JCO.2020.38.4_suppl.478","article-title":"Nivolumab (NIVO)+ipilimumab (IPI)+cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): results from CheckMate 040","volume":"38","author":"Yau","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl_5","key":"10.1016\/j.bulcan.2020.06.011_bib0425","first-page":"v851","article-title":"Randomised efficacy and safety results for atezolizumab (Atezo)+bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)","volume":"30","author":"Lee","year":"2019","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.bulcan.2020.06.011_bib0430","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1200\/JCO.2007.15.9947","article-title":"Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma","volume":"26","author":"Siegel","year":"2008","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.bulcan.2020.06.011_bib0435","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bulcan.2020.06.011_bib0440","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/ijc.30678","article-title":"Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis of published data","volume":"141","author":"Wang","year":"2017","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.bulcan.2020.06.011_bib0445","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.bulcan.2020.06.011_bib0450","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"Electronic address: easloffice@easloffice.eu, Clinical Practice Guideline Panel: Chair: Panel members, EASL Governing Board representative: EASL Clinical Practice Guidelines: Drug-induced liver injury","volume":"70","year":"2019","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.bulcan.2020.06.011_bib0455","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.jhep.2018.03.005","article-title":"Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines on hepatitis E virus infection","volume":"68","year":"2018","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.bulcan.2020.06.011_bib0460","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1634\/theoncologist.2018-0162","article-title":"Workup and management of immune-mediated hepatobiliary pancreatic toxicities that develop during immune checkpoint inhibitor treatment","volume":"25","author":"Hsu","year":"2020","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.bulcan.2020.06.011_bib0465","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1053\/j.semdp.2019.07.009","article-title":"Checkpoint inhibitor-induced liver injury: a novel form of liver disease emerging in the era of cancer immunotherapy","volume":"36","author":"Zen","year":"2019","journal-title":"Semin Diagn Pathol"},{"issue":"8","key":"10.1016\/j.bulcan.2020.06.011_bib0470","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/PAS.0000000000000453","article-title":"Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11\u00a0cases","volume":"39","author":"Johncilla","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.bulcan.2020.06.011_bib0475","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10637-017-0453-0","article-title":"Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer","volume":"35","author":"Kawakami","year":"2017","journal-title":"Invest New Drugs"},{"issue":"6","key":"10.1016\/j.bulcan.2020.06.011_bib0480","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/liv.13746","article-title":"Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents","volume":"38","author":"Suzman","year":"2018","journal-title":"Liver Int"},{"issue":"17","key":"10.1016\/j.bulcan.2020.06.011_bib0485","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"10.1016\/j.bulcan.2020.06.011_bib0490","doi-asserted-by":"crossref","first-page":"iv264","DOI":"10.1093\/annonc\/mdy162","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Haanen","year":"2018","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2020.06.011_bib0495","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jhep.2018.03.034","article-title":"Immune-related hepatitis with immunotherapy: are corticosteroids always needed?","volume":"69","author":"Gauci","year":"2018","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.bulcan.2020.06.011_bib0500","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jhep.2018.04.019","article-title":"Reply to: \u00ab\u00a0Immune-related hepatitis with immunotherapy: are corticosteroids always needed?\u00a0\u00bb","volume":"69","author":"De Martin","year":"2018","journal-title":"J Hepatol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745512030326X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745512030326X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:32:49Z","timestamp":1757791969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000745512030326X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S000745512030326X"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2020.06.011","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prise en charge des toxicit\u00e9s h\u00e9patiques sous immunoth\u00e9rapie anticanc\u00e9reuse","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2020.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}